Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neurología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
ClinicalTrials.gov
Retrospective Cohort Study of Rebif® Use in Pediatric MS Patients
OBSERVATIONAL
Inicio: 1 de jul de 2010
ID: NCT01207648
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease
INTERVENTIONAL
Inicio: 19 de abr de 2022
ID: NCT05256134
Desconocido
Fase 2
ClinicalTrials.gov
Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina
INTERVENTIONAL
Inicio: 3 de ago de 2021
ID: NCT04988048
Reclutando
Fase 2
ClinicalTrials.gov
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
INTERVENTIONAL
Inicio: 5 de may de 2020
ID: NCT03899155
Completado
Fase 4
ClinicalTrials.gov
MAESTRAL - A Prospective, Multinational, Multicenter, Randomized, Double Blind, Double Dummy, Controlled Study Comparing the Efficacy and Safety of Moxifloxacin to That of Amoxicillin Clavulanic Acid for the Treatment of Subjects With Acute Exacerbations of Chronic Bronchitis.
INTERVENTIONAL
Inicio: 1 de mar de 2008
ID: NCT00656747
Reclutando
Fase 2
ClinicalTrials.gov
A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease
INTERVENTIONAL
Inicio: 14 de ago de 2025
ID: NCT07105709
Completado
Fase 3
ClinicalTrials.gov
A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis
INTERVENTIONAL
Inicio: 30 de nov de 2009
ID: NCT00988221
Completado
ClinicalTrials.gov
Observational Study of Routine Ophthalmological Examinations of Patients Included in the 2 Bayer Sponsored Phase 3 Clinical Trials FIDELIO and FIGARO to Investigate the Effect of Finerenone on Delaying the Progression of Diabetic Retinopathy
OBSERVATIONAL
Inicio: 23 de jul de 2020
ID: NCT04477707
Completado
ClinicalTrials.gov
Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy
OBSERVATIONAL
Inicio: 1 de ago de 2011
ID: NCT01442194
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo Controlled, Single-dose Study to Assess the Initial Efficacy of Canakinumab (ACZ885) With Respect to the Adapted ACR Pediatric 30 Criteria in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations
INTERVENTIONAL
Inicio: 1 de jul de 2009
ID: NCT00886769
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48)
INTERVENTIONAL
Inicio: 1 de nov de 2008
ID: NCT00781391
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension
INTERVENTIONAL
Inicio: 28 de abr de 2022
ID: NCT05219617
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
INTERVENTIONAL
Inicio: 1 de mar de 2018
ID: NCT03312907
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations
INTERVENTIONAL
Inicio: 1 de jul de 2009
ID: NCT00889863
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study To Evaluate The Long-Term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis
INTERVENTIONAL
Inicio: 3 de may de 2022
ID: NCT05269004
Completado
Fase 4
ClinicalTrials.gov
A Multicenter, Randomized, Double-Period, Double - Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA)
INTERVENTIONAL
Inicio: 1 de dic de 2006
ID: NCT00420927
Completado
Fase 3
ClinicalTrials.gov
A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off
INTERVENTIONAL
Inicio: 1 de mar de 2011
ID: NCT01283594
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
INTERVENTIONAL
Inicio: 16 de jul de 2025
ID: NCT07011745
Terminado
Fase 3
ClinicalTrials.gov
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
INTERVENTIONAL
Inicio: 29 de oct de 2013
ID: NCT01975376
Reclutando
Fase 2
ClinicalTrials.gov
An Open-label, Single-arm Study to Evaluate Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis
INTERVENTIONAL
Inicio: 6 de oct de 2025
ID: NCT07161258
Anterior
1
...
29
30
31
...
434
Siguiente
Filtros